Skip to content
Review Open access

The heterogeneous and dynamic immune-tumor interface in breast cancer

Aug 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 81 references
Medicine

TL;DR

BCa progression therefore, reflects a balance between immune activation and suppression, governed by spatial organization and cellular stratification within the tumor microenvironment (TME).

Abstract

Breast cancer (BCa) progression is driven by ongoing interactions between evolving tumor cells and the host immune system. Antitumor immunity is not the same across all BCa subtypes and depends on the quality, localization, and functional state of immune cells within the tumor microenvironment (TME). Highly immunogenic subtypes, such as triple-negative and HER2-positive (+) BCa, generally show stronger immune infiltration and inflammatory signaling, whereas estrogen receptor–positive tumors more often display immune-desert or immune-excluded phenotypes with limited immune cell infiltration and effector activity. Effective immune surveillance requires not only the presence of immune cells, but also their suitable spatial localization and functional capacity. Cytotoxic CD8+ T cells mediate tumor control when they infiltrate tumor areas, whereas stromal-related limitations or functional exhaustion reduces their efficacy. This dysfunction is reinforced by regulatory populations, including FoxP3+ regulatory T cells and CD163+ tumor-associated macrophages, which establish suppressive networks that inhibit effector responses. Within this framework, T-cell immunity is organized into distinct functional states, including stem-like progenitor exhausted T cells, which maintain their immune potential, and effector T cells responsible for cytotoxicity, which support local surveillance. Tertiary lymphoid structures further enhance coordinated immune activation by serving as intratumoral sites of antigen presentation and lymphocyte priming. Immune escape arises through T-cell exhaustion, impaired antigen presentation, tumor-intrinsic signaling changes, and stromal barriers that restrict infiltration. Collectively, these mechanisms generate a regulated, but often tumor-supporting immune environment. BCa progression therefore, reflects a balance between immune activation and suppression, governed by spatial organization and cellular stratification within the TME.

Read PDF

Similar papers

Review Open access Sep 2026

Tumor microenvironment-driven immune evasion in triple-negative breast cancer: mechanisms, clinical challenges, and therapeutic opportunities

Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging breast cancer subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression. Because these classical therapeutic targets are lacking, chemotherapy remains a central systemic treatment; however, TNBC is fre...

Hui Zhang, Kun Zhou, Na Li et al. · 0 citations
Review Sep 2026

Tumor-infiltrating B cells in cancer immunity: heterogeneity, spatial organization, and context-dependent function.

Tumor-infiltrating B cells are emerging as critical regulators of cancer immunity. Recent single-cell and spatial studies have shown that their functions extend beyond antibody production to include antigen presentation, tertiary lymphoid structure (TLS) organization, T cell modulation, cytokine-mediated regulation, an...

Yi-Nuo Wang, Xuan Che, Xiao-Qian Hu et al. · 0 citations
Review Open access Aug 2026

Decoding the tumor microenvironment of triple-negative breast cancer: from immune evasion to precision immunotherapy

A review summarizes the dynamic landscape of the TNBC immune microenvironment, focusing on the functional roles of tumor-infiltrating lymphocytes, tumor-associated macrophages, tumor-associated neutrophils, natural killer cells, and myeloid-derived suppressor cells in regulating antitumor immunity and therapeutic resis...

Hong-Yu Cao, Mei Tao, Xue-Yi Qin et al. · 0 citations
Review Open access Oct 2026

The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable

Osteosarcoma (OSA) remains the most common primary malignant bone tumor of children and young adults, with limited survival improvements in patients with relapsed or metastatic disease despite multimodal chemotherapeutic treatment. Beyond the intrinsic heterogeneity and malignancy of tumor cells, OSA progression and th...

L. Tarone, I. Merighi, E. Tirtei et al. · 0 citations
Review Open access Oct 2026

Dynamic Immune Responsiveness in Breast Cancer: Tumor Microenvironment Plasticity, Therapeutic Timing, and Clinical Translation

Breast cancer immunotherapy has advanced substantially, yet durable clinical benefit remains limited to selected patient populations, reflecting heterogeneity in tumor–immune interactions across molecular subtypes, disease stages, and treatment contexts. This review frames immune responsiveness as a dynamic manifestati...

S. M. Nashir Udden, Monira Obaid, Laurentiu M. Pop et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.